Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Cenci, M Angela ^a   Ohlin, K Elisabet ^a   Rylander, Daniella ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

5 Hydroxytryptamine; Angiogenesis; D1; Dopamine receptor; Dopamine transporter; ERK1 2; Extracellular signal regulated kinases 1 and 2; Serotonin transporter

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE TRANSPORTER; ISRADIPINE; LEVODOPA; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN TRANSPORTER; TRANSCRIPTION FACTOR FOSB; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; BASAL GANGLION; BRAIN NERVE CELL; CELL PROLIFERATION; CORPUS STRIATUM; DENERVATION; DRUG MECHANISM; DYSKINESIA; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMAN; LONG TERM CARE; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE VESICLE; UPREGULATION;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MICROVESSELS; NEURONAL PLASTICITY; PARKINSON DISEASE; SEROTONIN;

EID: 71849091969     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70782-5     Document Type: Article

References (43)

1. Grandas F., Galiano M.L., and Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246 12 (1999) 1127-1133
2. Manson A., and Schrag A. Levodopa-induced dyskinesias, the clinical problem: clinical features, incidence, risk factors, management and impact on quality of life. In: Bezard E. (Ed). Recent breakthroughs in basal ganglia research (2006), Nova Science Publishers, New York 369-380
3. Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 26 8 (2005) 391-397
4. Cenci M.A., and Lundblad M. Postversus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99 2 (2006) 381-392
5. Foltynie T., Cheeran B., Williams-Gray C.H., Edwards M.J., Schneider S.A., Weinberger D., et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 80 2 (2009) 141-144
6. Morgante F., Espay A.J., Gunraj C., Lang A.E., and Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 129 Pt 4 (2006) 1059-1069
7. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9 9 (2008) 665-677
8. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., and Fisone G. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
9. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50 5 Suppl 5 (1998) S17-S25
10. Cenci M.A., and Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 17 6 (2007) 665-671
11. Lee J., Zhu W.M., Stanic D., Finkelstein D.I., Horne M.H., Henderson J., et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 131 Pt 6 (2008) 1574-1587
12. Troiano A.R., de la Fuente-Fernández R., Sossi V., Schulzer M., Mak E., Ruth T.J., et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 72 14 (2009) 1211-1216
13. Rylander D., Strome E., Mela F., Mercanti G., and Cenci M.A. The severity of L-DOPA-induced dyskinesia in the rat is positively correlated with the density of striatal serotonin afferents. Parkinsonism Relat Disord 13 Suppl 2 (2007) S90
14. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., and Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10 3 (1999) 631-634
15. Carta M., Carlsson T., Kirik D., and Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 Pt 7 (2007) 1819-1833
16. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., and Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem (2009) under revision.
17. Lindgren H.S., Ohlin K.E., and Cenci M.A. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 34 (2009) 2477-2488
18. Rascol O., Nutt J.G., Blin O., Goetz C.G., Trugman J.M., Soubrouillard C., et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58 2 (2001) 249-254
19. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22 12 (2002) 5042-5054
20. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76 (2001) 1-10
21. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27 26 (2007) 6995-7005
22. Westin J.E., Vercammen L., Strome E.M., Konradi C., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62 7 (2007) 800-810
23. Ingham C.A., Hood S.H., and Arbuthnott G.W. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 503 2 (1989) 334-338
24. Ingham C.A., Hood S.H., van Maldegem B., Weenink A., and Arbuthnott G.W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res 93 1 (1993) 17-27
25. Zaja-Milatovic S., Milatovic D., Schantz A.M., Zhang J., Montine K.S., Samii A., et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64 3 (2005) 545-547
26. 2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry 65 6 (2009) 518-526
27. Martinowich K., and Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33 1 (2008) 73-83
28. Mattson M.P., Maudsley S., and Martin B. BDNF and 5-HT: a dynamic duo in age related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27 10 (2004) 589-594
29. Henningsson S., Borg J., Lundberg J., Bah J., Lindstrom M., Ryding E., et al. Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men. Biol Psychiatry 66 5 (2009) 477-485
30. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131 Pt 1 (2008) 120-131
31. Boulet S., Mounayar S., Poupard A., Bertrand A., Jan C., Pessiglione M., et al. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 28 38 (2008) 9575-9584
32. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., and Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411 6833 (2001) 86-89
33. Chen Z.Y., Bath K., McEwen B., Hempstead B., and Lee F. Impact of genetic variant BDNF (Val66Met) on brain structure and function. Novartis Found Symp 289 (2008) 180-188 discussion: 188-95.
34. Guerini F.R., Beghi E., Riboldazzi G., Zangaglia R., Pianezzola C., Bono G., et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol 16 (2009) 1240-1245
35. Ferrario J.E., Taravini I.R., Mourlevat S., Stefano A., Delfino M.A., Raisman-Vozari R., et al. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem 90 6 (2004) 1348-1358
36. Konradi C., Westin J.E., Carta M., Eaton M.E., Kuter K., Dekundy A., et al. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17 2 (2004) 219-236
37. El Atifi-Borel M., Buggia-Prevot V., Platet N., Benabid A.L., Berger F., and Sgambato-Faure V. De novo and long-term L-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. Neurobiol Dis 34 2 (2009) 340-350
38. Farkas E., De Jong G.I., de Vos R.A., Jansen Steur E.N., and Luiten P.G. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 100 4 (2000) 395-402
39. Faucheux B.A., Bonnet A.M., Agid Y., and Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353 9157 (1999) 981-982
40. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 26 37 (2006) 9448-9461
41. Swain R.A., Harris A.B., Wiener E.C., Dutka M.V., Morris H.D., Theien B.E., et al. Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. Neuroscience 117 4 (2003) 1037-1046
42. Ivens S., Kaufer D., Flores L.P., Bechmann I., Zumsteg D., Tomkins O., et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 130 Pt 2 (2007) 535-547
43. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508